Hengrui Medicine (Jiangsu) Net Worth is5810.0 $Million
VN:F [1.9.22_1171]
deserves the money?
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.22_1171]
Would you date ?
Rating: 0.0/5 (0 votes cast)
Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
Apatinib was first synthesized by Advenchen Laboratories in California, USA and is being developed by Jiangsu Hengrui Medicine (China), LSK BioPartners (US) and Bukwang Pharmaceutical Company (Korea). It is an investigational cancer drug currently undergoing clinical trials as a potential targeted treatment for metastatic gastric carcinoma, metastatic breast cancer and advanced hepatocellular carcinoma.
The principal investigator from Fudan University, China, presented results of Phase I/II human clinical studies at the 2009 CSCO Meeting (October 17, 2009). Cancer patients were administered varied doses of Apatinib daily for 28 days. Apatinib was well tolerated at doses below 750 mg/day, 3 of 3 dose limiting toxicities were reported at 1000 mg/day and the maximum tolerated dose is determined to be 850 mg/day. The investigator also reported of 65 cancer patients treated in Phase I/II, 1.54% had a complete response, 12.31% had a partial response, 66.15% had stable disease and 20% had progressive disease.
A separate published report on the safety and pharmacokinetics of apatinib in Human clinical studies concludes that it has encouraging antitumor activity across a broad range of cancer types.
There is a Phase II/III study recruiting patients in China to determine whether apatinib can improve progression free survival compared with placebo in patients with metastatic gastric carcinoma who have failed two lines of chemotherapy (September, 2009).
As of November, 2010, two a

Hengrui Medicine (Jiangsu) Latest News

Jiangsu Hengrui Medicine : Hengrui Medicine c-Met ADC Wins FDA Approval for Clinic Test

2015 JIANGSU HENGRUI MEDICINE CO., LTD: ex-dividend day for annual dividend 2015 JIANGSU HENGRUI MEDICINE CO., LTD: BONUS ISSUE: 3 new shares for 10 existing sh.. 2014 JIANGSU HENGRUI MEDICINE CO., LTD: 10% Stock Dividend 2014 JIANGSU HENGRUI MEDICINE CO ...
Posted: January 25, 2017, 1:46 am

Ioversol Market Analysis, Segments, Growth and Value Chain 2016-2026

The market players in Ioversol market are Liebel-Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co., Mallinckrodt Pharmaceuticals, Ultraject, China Resources Pharmaceutical (Shanghai) Co., HB Ocean and many more. Future Market Insights (FMI ...
Posted: August 8, 2017, 9:47 pm

China stocks end higher on hopes for strong July data

Healthcare shares were also strong, rising 0.6 percent. Jiangsu Hengrui Medicine Co., the largest constituent of the CSI300 Health Care Index, rose 1.2 percent.
Posted: August 7, 2017, 12:25 am

Tencent, Ctrip, Baidu Among Six China Names On New Forbes Top Innovators List

Internet giant Tencent came in at No. 24, Kangde Xin Composite Material Group was No. 47, online travel firm Ctrip was No. 55, search leader Baidu came in at No. 60 and pharmaceuticals supplier Jiangsu Hengrui Medicine was No. 82. Click here for the full ...
Posted: August 8, 2017, 7:52 pm

Jiangsu Hengrui Medicine Announce Collaboration with Albert Einstein College of Medicine to Advance Cancer Research and Drug Discovery

Dr. Guoqing Cao, Vice President of Jiangsu Hengrui Medicine, commented: "Einstein is a prominent medical research institute with a long track record of achievements in advancing cancer research and fighting cancer. Hengrui is very pleased to partner with ...
Posted: April 25, 2016, 10:16 am
Related Topics:
Hengrui Medicine (Jiangsu), Hengrui Medicine (Jiangsu) Age, Hengrui Medicine (Jiangsu) Bio, Hengrui Medicine (Jiangsu) Country, Hengrui Medicine (Jiangsu) Date Of Birth, Hengrui Medicine (Jiangsu) Earnings, Hengrui Medicine (Jiangsu) Ethnicity, Hengrui Medicine (Jiangsu) Gossips, Hengrui Medicine (Jiangsu) Height, Hengrui Medicine (Jiangsu) History, Hengrui Medicine (Jiangsu) Home Town, Hengrui Medicine (Jiangsu) Images, Hengrui Medicine (Jiangsu) Income, Hengrui Medicine (Jiangsu) Job, Hengrui Medicine (Jiangsu) Nationality, Hengrui Medicine (Jiangsu) Net Worth, Hengrui Medicine (Jiangsu) Networth, Hengrui Medicine (Jiangsu) News, Hengrui Medicine (Jiangsu) Partner, Hengrui Medicine (Jiangsu) Place Of Birth, Hengrui Medicine (Jiangsu) Rumors, Hengrui Medicine (Jiangsu) Salary, Hengrui Medicine (Jiangsu) Secrets, Hengrui Medicine (Jiangsu) Videos, Hengrui Medicine (Jiangsu) Weight, How Much Is Hengrui Medicine (Jiangsu) Earnings, How Much Is Hengrui Medicine (Jiangsu) Income, How Much Is Hengrui Medicine (Jiangsu) Net Worth, How Much Is Hengrui Medicine (Jiangsu) Salary, How Much Is Hengrui Medicine (Jiangsu) Worth, Jiangsu Hengrui Medicine, Jiangsu Hengrui Medicine Annual Report, Jiangsu Hengrui Medicine Co, Jiangsu Hengrui Medicine Co Ltd China, Jiangsu Hengrui Medicine Co. Ltd, Jiangsu Hengrui Medicine Company, Jiangsu Hengrui Medicine Company Ltd, Jiangsu Hengrui Medicine Ltd, Who Is Hengrui Medicine (Jiangsu),